Skip to content

Friday, November 20, 2026

Mobile and Baldwin County News

Latest

University of South Alabama Mobile

Late Philanthropist Abe Mitchell’s $2 Million Gift Creates Urologic Cancer Chair at Mitchell Cancer Institute

A $2 million gift Abe Mitchell made before his October death endows a new urologic oncology chair at the USA Health Mitchell Cancer Institute, with urology chief Dr. Christopher Keel named its first holder.

Illustration of physicians reviewing a cancer case together around a conference table
Illustration

MOBILE, Ala. — Patients facing prostate, bladder and kidney cancer on the Gulf Coast stand to benefit from a new $2 million endowment at the USA Health Mitchell Cancer Institute, created through a gift from the late Abraham A. (Abe) Mitchell, one of the philanthropists whose family name the institute bears.

The gift establishes the Abraham A. Mitchell Chair in Urologic Oncology. Dr. Christopher E. Keel, D.O., FACS, who leads the Department of Urology at USA Health, has been named the first physician to hold the endowed position. The University of South Alabama announced the chair on Nov. 18.

Mitchell committed the money before his death on Oct. 15, making the endowment one of the final acts of a decades-long relationship between the Mobile businessman and the university.

Key Facts

  • Gift: $2 million from Abraham A. Mitchell, made before he died on Oct. 15
  • Position created: The Abraham A. Mitchell Chair in Urologic Oncology
  • Home: USA Health Mitchell Cancer Institute in Mobile
  • Inaugural chairholder: Dr. Christopher E. Keel, head of USA Health’s urology department
  • Focus: Advanced, coordinated care and clinical trials for patients with urologic cancers in the region
  • Announced: Nov. 18, 2026

A Plan to Link Departments Around Cancer Care

The new chair is the first piece of a larger idea Mitchell began pursuing last year. According to a member of his family, he wanted to build an endowment program that would tie individual medical departments within the university’s academic health system more closely to the cancer institute, so that cancers could be diagnosed and treated at MCI with the full weight of those specialties behind them.

Urology was chosen as the first department in that effort because urologic cancers are so common. Prostate cancer alone will affect roughly 1 in 8 men during their lifetimes, and cancers of the bladder and kidney strike both men and women. The family also has personal experience with these diseases: urologic cancers have touched several generations of Mitchell’s relatives, a connection the family said was not lost on him when he decided where to direct the gift.

What the Chair Is Meant to Accomplish

As the inaugural holder of the chair, Keel will work closely with the institute’s director, who came back to lead MCI in March. The two physicians are expected to concentrate on delivering advanced and compassionate treatment to urologic cancer patients and on expanding clinical trials across the region. The family has said the long-term aim is for MCI to become the leading center for urologic cancer care on the Gulf Coast.

Keel said he was humbled and honored by the gift. He described it as a commitment that reflects the legacy Mitchell hoped to leave, and he said the endowment will help the urology department recruit and develop top physicians and scientists, widen patient access to clinical trials and push forward research discoveries that improve patients’ lives. Keel, who said he knew Mitchell personally and considered him a friend, said the gift shows a deep conviction that people in this region should be able to get the best possible cancer care without leaving home, and that its effects will be felt by patients, physicians, trainees and researchers for generations.

Bringing the Specialists to the Patient

Leaders at the cancer institute see the chair as a way to reorganize how care is delivered. Rather than asking a patient to move from one specialist to another and manage those handoffs alone, the plan is to assemble the different disciplines involved in cancer treatment around each patient, the institute’s director said. The director added that the urology effort is intended to serve as a model for team-based, multidisciplinary care that could later be extended to other cancer programs within MCI.

Multidisciplinary care has become a widely used approach at major cancer centers. Treating a urologic cancer can involve urologists, medical oncologists who manage drug therapies, radiation oncologists, radiologists, pathologists, nurses and support staff. When those specialists review a case together, often in a regular tumor board meeting, patients can receive a coordinated treatment plan more quickly and with fewer separate appointments.

Understanding Urologic Cancers

Urologic oncology is the branch of medicine that treats cancers of the urinary tract and the male reproductive organs. The most common of these are:

  • Prostate cancer: The most frequently diagnosed cancer among American men other than skin cancer. Many cases grow slowly, but some are aggressive, which makes screening and careful evaluation important.
  • Bladder cancer: More common in men than women and strongly linked to smoking. Blood in the urine is often the first warning sign.
  • Kidney cancer: Frequently found by chance on imaging done for another reason. Risk factors include smoking, obesity and high blood pressure.
  • Testicular cancer: Less common, but one of the most frequent cancers among younger men, and highly treatable when found early.

People with concerns about symptoms such as blood in the urine, changes in urination or unexplained pain should talk with a doctor. Men are generally encouraged to discuss prostate cancer screening with their physicians, particularly as they reach middle age or if they have a family history of the disease.

Screening Conversations Start Earlier for Some Men

National cancer organizations generally advise men to talk with a health care provider about the pros and cons of prostate cancer screening, which usually involves a blood test for prostate-specific antigen, or PSA. For men at average risk, those conversations commonly begin around age 50. Men at higher risk, including Black men and men whose father or brother was diagnosed at a younger age, are often encouraged to start the discussion at 45, and men with several close relatives affected may begin even earlier.

There is no routine screening test recommended for the general population for bladder or kidney cancer, so knowing the warning signs and reporting them promptly is especially important. Quitting smoking is one of the most effective steps people can take to lower their risk of both.

Why Clinical Trials Matter

Expanding access to clinical trials is one of the central goals tied to the new chair. Clinical trials are research studies that test new treatments, drug combinations, surgical techniques or screening methods. For some patients, a trial can offer access to a promising therapy before it is widely available.

Historically, patients on the Gulf Coast have sometimes had to travel to larger medical centers in other states to enroll in certain studies. Building trial capacity locally can reduce that burden, and it also helps generate research data from a more representative population of patients.

How Endowed Chairs Work

An endowed chair is one of the most lasting forms of support a university can receive. The gift is typically invested, and a portion of the investment earnings is used each year to support the work of the person who holds the position. Because the principal is preserved, the chair can continue to support faculty, research and patient programs long after the original donation.

Universities use endowed positions to attract and retain leading physicians and scientists, to give them flexible resources for research, and to signal institutional commitment to a particular field. Holding a named chair is considered a significant honor in academic medicine.

The Mitchell Family’s Long Ties to South Alabama

Abraham Mitchell backed the University of South Alabama for many years. Together with his brother, Mayer Mitchell, his sister-in-law, Arlene Mitchell, and Gordon Moulton, who was then president of the university, he played a central role in making comprehensive, research-driven cancer treatment available along the Gulf Coast through the founding of the Mitchell Cancer Institute nearly 20 years ago.

Before the institute existed, many patients in south Alabama traveled long distances for specialized cancer treatment and research-based care. MCI was created to close that gap, combining patient care with laboratory and clinical research in Mobile. The institute is part of USA Health, the academic health system of the University of South Alabama, which also includes hospitals, physician practices and the university’s medical school.

Leadership at the Cancer Institute

The announcement comes during a period of renewed leadership at MCI. The institute’s director returned to lead the cancer center in March, and the new endowed chair gives that leadership team a dedicated partner in urology. The pairing is intended to strengthen collaboration between the cancer institute and one of the university’s clinical departments, a step the Mitchell family hopes will be followed by similar partnerships with other specialties.

A Legacy Focused on Patients Close to Home

The new chair reflects a theme that ran through much of Mitchell’s philanthropy: the belief that people living along the Gulf Coast should not have to leave the region to receive advanced medical care. By directing his final major gift toward a common group of cancers and toward the people who treat them, Mitchell sought to give the cancer institute a durable source of support for recruiting talent, running research studies and coordinating care.

For patients and families in Mobile and across the region, the practical outcome the university is aiming for is straightforward: more specialists, more research options and a more organized path through treatment for people diagnosed with prostate, bladder, kidney and other urologic cancers.

See something? Say something.

Got a news tip?

The best local stories start with readers. Tell our newsroom what is happening in your community.